The COVID-19 inactivated vaccine produced by Sinopharm China National Biotech Wuhan Institute of Biological Products was launched for public use on Sunday, making it the third domestically produced vaccines available in the market.
The Wuhan Institute of Biological Products built a biosafety workshop for the COVID-19 inactivated vaccines, which has been inspected and certified by relevant national authorities and has been put into large-scale production. The workshop can reach an annual output of about 100 million doses.
Since July 16, 2020, the Wuhan Institute of Biological Products conducted phase III clinical trials of COVID-19 inactivated vaccine in countries, including the United Arab Emirates, which adopted an international multi-center, randomized, double-blind, placebo parallel controlled design.
The results of phase III clinical trials have met the technical standards of the World Health Organization and the State Drug Administration.
The Central China Biological Industry Base, located in Jiangxia District, Wuhan, Hubei Province, was also unveiled on Sunday. The base will focus on the projects of the Wuhan Institute of Biological Products, and make efforts in three major areas of vaccines, blood products, and therapeutic biological drugs. It plans to develop and manufacture seven to ten new products and become a modern biopharmaceutical industrial base.
(Compiled by Liu Kechen)